Management of High‑Risk Gleason 9 Prostate Cancer with Nodal Involvement

Primary Treatment Recommendation

Radiation Dose and Technique

Hormonal Therapy and Androgen‑Pathway Inhibition

Node‑Positive Disease Management

Surgical Considerations (Radical Prostatectomy)

Brachytherapy Boost Option

Staging, Monitoring, and Follow‑Up

Critical Pitfalls to Avoid

Additional Systemic Intensification (Optional)

Radiation‑Based Trimodality Therapy for High‑Risk (Gleason 9) Prostate Cancer

External Beam Radiation Dose and Long‑Term ADT

• In patients with Gleason 9 disease, dose‑escalated external‑beam radiotherapy (≥ 75.6 Gy) combined with long‑term androgen‑deprivation therapy (2–3 years) yields an approximate 10‑year overall survival of 72 % and a biochemical‑control rate of 77 %【1】.
• Long‑term ADT (≥ 2 years) is mandatory; the RTOG 92‑02 randomized trial demonstrated a 45 % 10‑year overall survival with long‑term ADT versus 32 % with short‑term ADT, representing a 40 % relative improvement (P = 0.0061)【1】.

Outcomes of Radical Prostatectomy Compared with Radiation‑Based Strategies

• Radical prostatectomy for Gleason 8–10 disease achieves only 36 % progression‑free survival; nearly half of patients (≈ 49 %) require local salvage therapy and 30 % need systemic salvage【1】.
• Compared with radical prostatectomy, combined external‑beam radiotherapy plus brachytherapy boost with ADT reduces prostate‑cancer‑specific mortality by 62 % (hazard ratio 0.38, 95 % CI 0.21–0.68) and distant metastasis by 73 % (hazard ratio 0.27, 95 % CI 0.17–0.43)【1】.

Androgen‑Deprivation Therapy Duration and Monotherapy

• Short‑term ADT (≤ 6 months) markedly lowers 10‑year survival (from 45 % to 32 %) compared with long‑term ADT, confirming that short‑term ADT is inappropriate for Gleason 9 disease【1】.
• ADT used alone, without concurrent radiation, does not provide curative intent and fails to improve survival for localized high‑risk prostate cancer【1】.

Brachytherapy Boost – Patient Selection and Limitations

• Brachytherapy as a sole modality is markedly inferior for Gleason 9 disease, resulting in poor biochemical control【1】.
• A brachytherapy boost is contraindicated in patients with pre‑existing obstructive urinary symptoms, very large or very small prostates, or a history of transurethral resection of the prostate; good baseline urinary function is required【2】.

Extended Pelvic Lymph Node Dissection (ePLND)

• Performing an extended pelvic lymph‑node dissection that removes all nodal tissue from the external iliac vein to Cooper’s ligament detects nodal metastases twice as often as a limited dissection, supporting its use when surgery is contemplated【2】.